We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

9 hedge funds and large institutions have $1.54M invested in Akari Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

398% more capital invested

Capital invested by funds: $308K → $1.54M (+$1.23M)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

50% more funds holding

Funds holding: 6 → 9 (+3)

12.96% more ownership

Funds ownership: 0.15% → 13.1% (+13%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
9
Holders Change
+3
Holders Change %
+50%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
1
Closed
2
Calls
$102K
Puts
–
Net Calls
+$102K
Net Calls Change
+$102K

Top Buyers

Rank Fund Capital Flow
1
MI
MMCAP International
Cayman Islands
+$863K
2
Jane Street
Jane Street
New York
+$133K
3
HF
HRT Financial
New York
+$119K
4
SS
SBI Securities
Japan
+$78
5
CIAM
Caitong International Asset Management
Hong Kong
+$69

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$200K
2
IA
IFP Advisors
Florida
-$62.5K
3
Morgan Stanley
Morgan Stanley
New York
-$5

AKTX Hedge Fund Activity: Q2 2026 in Review

9 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2026, worth a combined $1.54M — up 398% from $308K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new AKTX positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was MMCAP International, opening a new position worth an estimated $863K. The largest seller was Armistice Capital, exiting entirely with an estimated $200K sold.

  • 9 institutional investors held Akari Therapeutics (AKTX) as of Q2 2026, up from 6 in Q1 2026.
  • Funds reported $1.54M of Akari Therapeutics stock for Q2 2026, up 398% quarter-over-quarter.
  • 5 funds opened new Akari Therapeutics positions in Q2 2026 and 2 closed out, a net change of +3 holders.
  • The largest Akari Therapeutics buyer in Q2 2026 was MMCAP International, an estimated $863K added.
  • The largest Akari Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $200K sold.

Based on aggregated 13F filings for Q2 2026.